Contraception during perimenopause

European Journal of Contraception and Reproductive Health Care

Volumn 10, Issue 1, 2005, Pages 19-25

  Kailas, N A ^a   Sifakis, S ^a   Koumantakis, E ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Barrier contraceptive methods; Contraception; Hormonal injectables and implants; IUDs; Oral contraceptives; Perimenopause; Tubal ligation

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTODENE; INJECTABLE CONTRACEPTIVE AGENT; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BARRIER CONTRACEPTION; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CLINICAL TRIAL; COLORECTAL CANCER; CONTRACEPTION; DEPRESSION; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANT; DYSMENORRHEA; ENDOMETRIUM ATROPHY; ENDOMETRIUM CANCER; FEMALE STERILIZATION; FERTILITY; GYNECOLOGIC CANCER; HEADACHE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; META ANALYSIS; ORAL CONTRACEPTION; OSTEOLYSIS; OSTEOPOROSIS; OVARY CANCER; OVARY FUNCTION; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TRANSDERMAL PATCH; UTERINE TUBE LIGATION; VAGINA RING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

CONTRACEPTION; CONTRACEPTIVE AGENTS; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES; MIDDLE AGED; PATIENT SATISFACTION; PERIMENOPAUSE; PREGNANCY; PREGNANCY RATE; PREGNANCY, UNWANTED; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STERILIZATION, REPRODUCTIVE;

EID: 20344406215     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625180400020861     Document Type: Article

References (70)

1. McKinley SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-15.
2. Toner JP, Flood JT. Fertility after the age of 40. Obstet Gynecol Clin North Am 1993;20:261-72.
3. Schmidt-Sarosi C. Infertility in the older woman. Clin Obstet Gynecol 1998;41:940-50.
4. Richardson SJ, Senicas V, Nelson JF. Follicular depletion during the menopausal transition - evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987;65:1231-7.
5. Klein NA, Illingworth PJ, Groome NP, et al. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996;81:2742-5.
6. Welt CK, McNicholl DJ, Taylor AE, et al. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999;84:105-11.
7. MacNaughton J, Bangah M, McCloud P, et al. Age-related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol 1992;36:339.
8. Burger HG, Dudley EC, Robertson DM, et al. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-75.
9. Hee J, MacNaughton J, Bangah M, et al. Perimenopausal patterns of gonadotropins, imunoreactive inhibin, oestradiol and progesterone. Matuntas 1993;18:9-20.
10. Treloar AE. Menstrual cyclicity and the premenopause. Maturitas 1981;3:249-64.
11. Seltzer VL, Benjamin F, Deutch S. Perimenopausal bleeding patterns and pathologic findings. J Am Med Womens Assoc 1990;45:132-4.
12. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86.
13. Bachmann G. Sexual issues at menopause. Ann N Y Acad Sci 1990;592:87-92.
14. Forrest JD. Epidemiology of unintended pregnancy and contraceptive use. Am J Obstet Gynecol 1994;170:1485-9.
15. Jolly M, Sebire N, Haris J, et al. The risks associated with pregnancy in women aged 35 years or older. Hum Reprod 2000;15:2433-7.
16. Hook EB, Cross PK, Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA 1983;249:2034-8.
17. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ 2000;320(7251):1708-12.
18. Williams JK. Contraceptive needs of the perimenopausal woman. Obstet Gynecol Clin North Am 2002;29:575-88, ix.
19. Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the US Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174:1161-70.
20. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal sterilization, hysterectomy, and the risk of ovarian cancer: a prospective study. JAMA 1993;270:2813-19.
21. Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithilium and risk of ovarian cancer. Epidemiology 2000;11:111-17.
22. Peterson HB, Jeng G, Folger SG, et al. The risk of menstrual abnormalities after tubal sterilization: findings from the US Collaborative Review of Sterilization. N Engl J Med 2000;343:1681-7.
23. Hillis SD, Marchbanks PA, Tylor LR, et al. Posterilization regret: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 1999;93:889-95.
24. Fu H, Darroch JE, Haas T, et al. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:56-6
25. Kelaghan J, Rubin GL, Ory HW, et al. Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982;248:184-7.
26. Parazzini F, Negri E, La Vecchia C, et al. Barrier methods of contraception and the risk of cervical neoplasia. Contraception 1989;40:519-30.
27. Kaunitz AM. Current concepts regarding use of DMPA. J Reprod Med 2002;47(Suppl.):785-9.
28. Berenson AB, Radecki CM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001;98:576-82.
29. Kaunitz AM. Lunelle monthly injectable contraception: an effective, safe, and convenient new birth control option. Arch Gynecol Obstet 2001;265:119-23.
30. Brache V, Faundes A, Alvarez F. Risk-benefit effects of implantable contraceptives in women. Expert Opin Drug Saf 2003;2:321-32.
31. Darney PD. Hormonal implants: contraception for a new century. Am J Obstet Gynecol 1994;170:1536-43.
32. Davies GC, Li XF, Newton JR, et al. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3 Keto desogestrel. Contraception 1993;47:251-61.
33. Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception 2003;68:31-4
34. Sivin I, Stern J, Coutinho E. Prolonged intrauterine contraception: a seven-year. Contraception 1991;44:473-80.
35. Sivin I, Stern J. Health during prolonged use of levonogestrel 20 micrograms/d and the copper Tcu 380A intrauterine contraceptive devices: a multicenter study. Fertil Steril 1994;61:70-7.
36. Onyeka BA. Levonorgestrel-releasing (20mcg/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. Br J Obstet Gynecol 2001;108:770-1.
37. Wildemeersch D, Schacht E, Wildemeersch P. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women. Maturitas 2003;44:237-45.
38. th edition. New York: Ardent Media Inc, 1998:779-844.
39. Ortho-McNeil P. Ortho Annual Birth Control Study 1999. Raritan, NJ: Ortho-McNeil Pharmaceutical, 2000.
40. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives:collaborative reanalysis of individual data on 53,297 with breast cancer and 100,239 women without breast cancer from 54 epidimiological studies. Lancet 1996;347:1713-27.
41. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159-67.
42. Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25 year follow-up of cohort of 46000 women from Royal College of General Practitioners' oral contraceptive study. BMJ 1999;318(7176):96-100.
43. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92.
44. Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: results from the transnational study on oral contraceptives and the health of young women. Contraception 1997;56:129-40.
45. WHO Scientific Group. Cardiovascular disease and steroid contraception: report of a WHO scientific group. Technical Report 877. Geneva: World Health Organisation, 1998.
46. Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose contraceptives. N Engl J Med 1996;335:8-15.
47. Sidney S, Petitti DB, Quesenberry CP. Myocardial infarction in user of low-dose oral contraceptives. Obstet Gynecol 1996;88:939-44.
48. Consensus conference on combination oral contraceptives and cardiovascular disease. Fertil Steril 1999;71(suppl. 3):1S-6S.
49. Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynecol 1995;15:195-200.
50. Purdie DM, Bain CJ, Siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003; 20:104:228-32.
51. Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;316:650-5.
52. Siskind V, Green A, Bain C, et al. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 2000;11:106-10.
53. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998;339:424-8.
54. Modan B, Hartge P, Hirsch-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;26:345:235-40.
55. Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development.Combination. Oral contraceptive use and the risk of endometrial cancer. JAMA 1987;257:796-800.
56. Weiderpass E, Adami HO, Baron JA, et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-84.
57. Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception 1991;43:557-79.
58. Fernandez E, LaVecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001;84:72-727.
59. Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982;144:630-5.
60. Wolner-Hanssen P, Eschenbach DA, Paavonen J, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptives. JAMA 1990;263:54-9.
61. Vessey M, Metcalfe A, Wells C, et al. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. BMJ 1987;294:1518-20.
62. Lanes SF, Birmann B, Walker AM, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-61.
63. Brinton LA, Vessey MP, Flavel R, et al. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-14.
64. Michaelsson K, Baron JA, Farahmand BY, et al. Oral contraceptive use and the risk of hip fracture:a case-control study. Lancet 1999;353:1481-4.
65. Jorgensen C, Picot MC, Bologna C, et al. Oral contraception, parity, breastfeeding, and severity of rheumatoid arthritis. Ann Rheum Dis 1996;55:94-8.
66. Apgar BS. Dysmenorrhea and dysfunctional uterine bleeding. Prim Care 1997;24:161-78.
67. Larsson G, Milsom I, Lindstedt G, et al. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992;46:327-34.
68. Mulders TM, Dieben TO. Use of the novel combined cotraceptive vaginal ring (Nuvaring) for ovulation inhibition. Fertil Steril 2001;75:865-70.
69. Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001;98:799-805.
70. Burkman RT. The transdermal contraceptive patch:a new approach to hormonal contraception. Int J Fertil Womens Med 2002;47:69-76.